Diagnosis and therapy of carcinoid tumors-current state of the art and future directions

Nuclear Medicine and Biology

Volumn 35, Issue SUPPL.1, 2008, Pages

  Khan, Mazhar U ^a   Coleman, R Edward ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Carcinoid tumors; Diagnosis; Therapy

Indexed keywords

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID (1 DEXTRO PHENYLALANINE 3 TYROSINE)OCTREOTATE GA 68; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID 3 TYROSINE OCTREOTATE LU 177; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSINE OCTREOTATE LU 177; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSINE OCTREOTIDE YT 90; 5 HYDROXYTRYPTOPHAN C 11; ALPHA INTERFERON; ANGIOPEPTIN; BETA INTERFERON; CISPLATIN; DIHYDROXYPHENALALANINE C 11; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; FLUORODIHYDROXYPHENYLALANINE F 18; FLUORODOPA F 18; FLUOROURACIL; OCTREOTATE LU 177; OCTREOTIDE; PENTETATE INDIUM IN 111; PENTETREOTIDE; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; SCLEROSING AGENT; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VAPREOTIDE; YTTRIUM 90;

ABDOMINAL PAIN; ADD ON THERAPY; BONE MARROW SUPPRESSION; CANCER CLASSIFICATION; CARCINOID; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DEPRESSION; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DRUG DOSE TITRATION; FATIGUE; GALLSTONE; HEART ARRHYTHMIA; HEART MUSCLE CONDUCTION DISTURBANCE; HISTOLOGY; HUMAN; HYPOTHYROIDISM; IMPAIRED GLUCOSE TOLERANCE; ISOTOPE LABELING; LEUKOCYTE; LIVER METASTASIS; METASTASIS; MOLECULAR IMAGING; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PARALYSIS; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RADIOFREQUENCY ABLATION; REVIEW; SCINTIGRAPHY; SCLEROTHERAPY; SEROTONIN BLOOD LEVEL; STEATORRHEA; VOMITING; WORLD HEALTH ORGANIZATION;

EID: 49049098454     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2008.05.008     Document Type: Review

References (120)

1. Lubarsch O. Über den primären Krebs des Ileum, nebst Bemerkungen über das gleichzeitige Vorkommen von Krebs und Tuberkolose. Virchows Arch 111 (1888) 280-317
2. Godwin II J.D. Carcinoid tumors. An analysis of 2,837 cases. Cancer 36 (1975) 560-569
3. Modlin I.M., and Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 79 (1997) 813-829
4. Kulke M.H., and Mayer R.J. Carcinoid tumors. N Engl J Med 340 (1999) 858-868
5. Berge T., and Linell F. Carcinoid tumours. Frequency in a defined population during a 12-year period. Acta Pathol Microbiol Scand [A] 84 (1976) 322-330
6. Modlin I.M., Lye K.D., and Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97 (2003) 934-959
7. Oberg K., Astrup L., Eriksson B., Falkmer S.E., Falkmer U.G., Gustafsen J., et al. Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I - General overview. Acta Oncol 43 (2004) 617-625
8. Horton K.M., Kamel I., Hofmann L., and Fishman E.K. Carcinoid tumors of the small bowel: a multitechnique imaging approach. AJR Am J Roentgenol 182 (2004) 559-567
9. Picus D., Glazer H.S., Levitt R.G., and Husband J.E. Computed tomography of abdominal carcinoid tumors. AJR Am J Roentgenol 143 (1984) 581-584
10. Tamm EP, Kim EE, Ng CS. Imaging of neuroendocrine tumors. Hematol Oncol Clin North Am 2007;21:409-32; vii.
11. Calender A. Molecular genetics of neuroendocrine tumors. Digestion 62 Suppl 1 (2000) 3-18
12. Debelenko L.V., Zhuang Z., Emmert-Buck M.R., Chandrasekharappa S.C., Manickam P., Guru S.C., et al. Allelic deletions on chromosome 11q13 in multiple endocrine neoplasia type 1-associated and sporadic gastrinomas and pancreatic endocrine tumors. Cancer Res 57 (1997) 2238-2243
13. Kytola S., Nord B., Elder E.E., Carling T., Kjellman M., Cedermark B., et al. Alterations of the SDHD gene locus in midgut carcinoids, Merkel cell carcinomas, pheochromocytomas, and abdominal paragangliomas. Genes Chromosomes Cancer 34 (2002) 325-332
14. Neumann H.P., Pawlu C., Peczkowska M., Bausch B., McWhinney S.R., Muresan M., et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 292 (2004) 943-951
15. Solcia E., Capella C., Fiocca R., Rindi G., and Rosai J. Gastric argyrophil carcinoidosis in patients with Zollinger-Ellison syndrome due to type 1 multiple endocrine neoplasia. A newly recognized association. Am J Surg Pathol 14 (1990) 503-513
16. Lehy T., Cadiot G., Mignon M., Ruszniewski P., and Bonfils S. Influence of multiple endocrine neoplasia type 1 on gastric endocrine cells in patients with the Zollinger-Ellison syndrome. Gut 33 (1992) 1275-1279
17. Moertel C.G., Sauer W.G., Dockerty M.B., and Baggenstoss A.H. Life history of the carcinoid tumor of the small intestine. Cancer 14 (1961) 901-912
18. Burke A.P., Thomas R.M., Elsayed A.M., and Sobin L.H. Carcinoids of the jejunum and ileum: an immunohistochemical and clinicopathologic study of 167 cases. Cancer 79 (1997) 1086-1093
19. Rosenberg J.M., and Welch J.P. Carcinoid tumors of the colon. A study of 72 patients. Am J Surg 149 (1985) 775-779
20. Buck J.L., and Sobin L.H. Carcinoids of the gastrointestinal tract. Radiographics 10 (1990) 1081-1095
21. Robertson R.G., Geiger W.J., and Davis N.B. Carcinoid tumors. Am Fam Phys 74 (2006) 429-434
22. Eriksson B., Oberg K., and Stridsberg M. Tumor markers in neuroendocrine tumors. Digestion 62 Suppl 1 (2000) 33-38
23. Feldman J.M., and O'Dorisio T.M. Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors. Am J Med 81 (1986) 41-48
24. Oberg K., Kvols L., Caplin M., Delle Fave G., de Herder W., Rindi G., et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 15 (2004) 966-973
25. Jensen T.B., Hilsted L., and Rehfeld J.F. Library of sequence-specific radioimmunoassays for human chromogranin A. Clin Chem 45 (1999) 549-560
26. Oberg K., Janson E.T., and Eriksson B. Tumour markers in neuroendocrine tumours. Ital J Gastroenterol Hepatol 31 Suppl 2 (1999) S160-S162
27. Nehar D., Lombard-Bohas C., Olivieri S., Claustrat B., Chayvialle J.A., Penes M.C., et al. Interest of chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol (Oxf) 60 (2004) 644-652
28. Janson E.T., Holmberg L., Stridsberg M., Eriksson B., Theodorsson E., Wilander E., et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 8 (1997) 685-690
29. Woodard P.K., Feldman J.M., Paine S.S., and Baker M.E. Midgut carcinoid tumors: CT findings and biochemical profiles. J Comput Assist Tomogr 19 (1995) 400-405
30. Sugimoto E., Lorelius L.E., Eriksson B., and Oberg K. Midgut carcinoid tumours. CT appearance. Acta Radiol 36 (1995) 367-371
31. Lamberts S.W., Bakker W.H., Reubi J.C., and Krenning E.P. Somatostatin receptor imaging in vivo localization of tumors with a radiolabeled somatostatin analog. J Steroid Biochem Mol Biol 37 (1990) 1079-1082
32. Kaltsas G., Korbonits M., Heintz E., Mukherjee J.J., Jenkins P.J., Chew S.L., et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab 86 (2001) 895-902
33. Kvols L.K., Brown M.L., O'Connor M.K., Hung J.C., Hayostek R.J., Reubi J.C., et al. Evaluation of a radiolabeled somatostatin analog (I-123 octreotide) in the detection and localization of carcinoid and islet cell tumors. Radiology 187 (1993) 129-133
34. Brazeau P., Vale W., Burgus R., Ling N., Butcher M., Rivier J., et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179 (1973) 77-79
35. Pauwels S., Leners N., Fiasse R., and Jamar F. Localization of gastroenteropancreatic neuroendocrine tumors with 111indium-pentetreotide scintigraphy. Semin Oncol 21 (1994) 15-20
36. 123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20 (1993) 716-731
37. Schillaci O., Scopinaro F., Angeletti S., Tavolaro R., Danieli R., Annibale B., et al. SPECT improves accuracy of somatostatin receptor scintigraphy in abdominal carcinoid tumors. J Nucl Med 37 (1996) 1452-1456
38. Schillaci O., Scopinaro F., Danieli R., Angeletti S., Tavolaro R., Annibale B., et al. Single photon emission computerized tomography increases the sensitivity of indium-111-pentetreotide scintigraphy in detecting abdominal carcinoids. Anticancer Res 17 (1997) 1753-1756
39. Schillaci O., Corleto V.D., Annibale B., Scopinaro F., and Delle Fave G. Single photon emission computed tomography procedure improves accuracy of somatostatin receptor scintigraphy in gastro-entero pancreatic tumours. Ital J Gastroenterol Hepatol 31 Suppl 2 (1999) S186-S189
40. Gibril F., Reynolds J.C., Doppman J.L., Chen C.C., Venzon D.J., Termanini B., et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 125 (1996) 26-34
41. 131I]iodobenzylguanidine. J Nucl Med 21 (1980) 349-353
42. Hoefnagel C.A., den Hartog Jager F.C., Taal B.G., Abeling N.G., and Engelsman E.E. The role of I-131-MIBG in the diagnosis and therapy of carcinoids. Eur J Nucl Med 13 (1987) 187-191
43. Oberg K., and Eriksson B. Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours. Best Pract Res Clin Endocrinol Metab 19 (2005) 265-276
44. Le Rest C., Bomanji J.B., Costa D.C., Townsend C.E., Visvikis D., and Ell P.J. Functional imaging of malignant paragangliomas and carcinoid tumours. Eur J Nucl Med 28 (2001) 478-482
45. Zuetenhorst J.M., Hoefnageli C.A., Boot H., Valdes Olmos R.A., and Taal B.G. Evaluation of (111)In-pentetreotide, (131)I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease. Nucl Med Commun 23 (2002) 735-741
46. Hanson M.W., Feldman J.M., Blinder R.A., Moore J.O., and Coleman R.E. Carcinoid tumors: iodine-131 MIBG scintigraphy. Radiology 172 (1989) 699-703
47. Nocaudie-Calzada M., Huglo D., Carnaille B., Proye C., and Marchandise X. Comparison of somatostatin analogue and metaiodobenzylguanidine scintigraphy for the detection of carcinoid tumours. Eur J Nucl Med 23 (1996) 1448-1454
48. Ramage J.K., Williams R., and Buxton-Thomas M. Imaging secondary neuroendocrine tumours of the liver: comparison of I123 metaiodobenzylguanidine (MIBG) and In111-labelled octreotide (Octreoscan). QJM 89 (1996) 539-542
49. Carnaille B., Nocaudie M., Pattou F., Huglo D., Deveaux M., Marchandise X., et al. Scintiscans and carcinoid tumors. Surgery 116 (1994) 1118-1121 [discussion 21-2]
50. 111In-pentetreotide in carcinoid tumours. Eur J Cancer 32A (1996) 1924-1932
51. Bomanji J., Mather S., Moyes J., Ellison D., Grossman A., Britton K.E., et al. A scintigraphic comparison of iodine-123-metaiodobenzylguanidine and an iodine-labeled somatostatin analog (Tyr-3-octreotide) in metastatic carcinoid tumors. J Nucl Med 33 (1992) 1121-1124
52. Kaltsas G.A., Besser G.M., and Grossman A.B. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 25 (2004) 458-511
53. Kaltsas G., Rockall A., Papadogias D., Reznek R., and Grossman A.B. Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur J Endocrinol 151 (2004) 15-27
54. Adams S., Baum R., Rink T., Schumm-Drager P.M., Usadel K.H., and Hor G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 25 (1998) 79-83
55. Eriksson B., Bergstrom M., Sundin A., Juhlin C., Orlefors H., Oberg K., et al. The role of PET in localization of neuroendocrine and adrenocortical tumors. Ann N Y Acad Sci 970 (2002) 159-169
56. 18F dopa PET for detection of gastrointestinal carcinoid tumors. Radiology 220 (2001) 373-380
57. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 48 (2007) 508-518
58. 18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. J Nucl Med 49 (2008) 573-586
59. 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol 7 (2006) 728-734
60. Kayani I., Bomanji J.B., Groves A., Conway G., Gacinovic S., Win T., et al. Functional imaging of neuroendocrine tumors with combined PET/CT using (68)Ga-DOTATATE (DOTA-DPhe(1),Tyr(3)-octreotate) and (18)F-FDG. Cancer (2008)
61. Maecke H.R., Hofmann M., and Haberkorn U. (68)Ga-Labeled peptides in tumor imaging. J Nucl Med 46 Suppl 1 (2005) 172S-178S
62. 68Ga. Eur J Nucl Med Mol Imaging 32 (2005) 478-485
63. Hofmann M., Maecke H., Borner R., Weckesser E., Schoffski P., Oei L., et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 28 (2001) 1751-1757
64. 111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 5 (2003) 42-48
65. 11C] 5-hydroxy-l-tryptophan uptake and decarboxylation in carcinoid tumors by specific positioning labeling in positron emission tomography. Nucl Med Biol 27 (2000) 33-41
66. Gerasimou G.P., Aggelopoulou T., Papanastasiou E., Konidari-Dedousi E., Prousalidis I., Psarrakos K., et al. Indium-111-DTPA-phenyl-pentetreotide somatostatin receptors' scintigraphy in the evaluation of patients with suspected gastro-entero-pancreatic tumors. Comparison with computerized tomography. Hell J Nucl Med 10 (2007) 209-214
67. Mathonnet M. Gastrointestinal carcinoid tumors: a multi-technique diagnostic approach. J Chir (Paris) 144 (2007) 287-292
68. Schally A.V. Oncological applications of somatostatin analogues. Cancer Res 48 (1988) 6977-6985
69. Hillman N., Herranz L., Alvarez C., Martinez Olmos M.A., Marco A., and Gomez-Pan A. Efficacy of octreotide in the regression of a metastatic carcinoid tumour despite negative imaging with In-111-pentetreotide (Octreoscan). Exp Clin Endocrinol Diabetes 106 (1998) 226-230
70. Kvols L.K., Moertel C.G., O'Connell M.J., Schutt A.J., Rubin J., and Hahn R.G. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 315 (1986) 663-666
71. Thulin L., Samnegard H., Tyden G., Long D.H., and Efendic S. Efficacy of somatostatin in a patient with carcinoid syndrome. Lancet 2 (1978) 43
72. Bauer W., Briner U., Doepfner W., Haller R., Huguenin R., Marbach P., et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 31 (1982) 1133-1140
73. Wymenga A.N., Eriksson B., Salmela P.I., Jacobsen M.B., Van Cutsem E.J., Fiasse R.H., et al. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol 17 (1999) 1111
74. O'Toole D., Ducreux M., Bommelaer G., Wemeau J.L., Bouche O., Catus F., et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, tolerance. Cancer 88 (2000) 770-776
75. Leong W.L., and Pasieka J.L. Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and a review of the literature. J Surg Oncol 79 (2002) 180-187
76. Nilsson O., Kolby L., Wangberg B., Wigander A., Billig H., William-Olsson L., et al. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours. Br J Cancer 77 (1998) 632-637
77. Garland J., Buscombe J.R., Bouvier C., Bouloux P., Chapman M.H., Chow A.C., et al. Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience. Aliment Pharmacol Ther 17 (2003) 437-444
78. Ruszniewski P., Ducreux M., Chayvialle J.A., Blumberg J., Cloarec D., Michel H., et al. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut 39 (1996) 279-283
79. Ricci S., Antonuzzo A., Galli L., Orlandini C., Ferdeghini M., Boni G., et al. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Am J Clin Oncol 23 (2000) 412-415
80. Ducreux M., Ruszniewski P., Chayvialle J.A., Blumberg J., Cloarec D., Michel H., et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 95 (2000) 3276-3281
81. Schnirer I.I., Yao J.C., and Ajani J.A. Carcinoid - a comprehensive review. Acta Oncol 42 (2003) 672-692
82. Janson E.T., and Oberg K. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol 32 (1993) 225-229
83. Frank M., Klose K.J., Wied M., Ishaque N., Schade-Brittinger C., and Arnold R. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 94 (1999) 1381-1387
84. Oberg K. Chemotherapy and biotherapy in neuroendocrine tumors. Curr Opin Oncol 5 (1993) 110-120
85. Tiensuu Janson E.M., Ahlstrom H., Andersson T., and Oberg K.E. Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumours. Eur J Cancer 28A (1992) 1647-1650
86. Oberg K., and Eriksson B. The role of interferons in the management of carcinoid tumors. Acta Oncol 30 (1991) 519-522
87. Kolby L., Persson G., Franzen S., and Ahren B. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg 90 (2003) 687-693
88. Saltz L., Trochanowski B., Buckley M., Heffernan B., Niedzwiecki D., Tao Y., et al. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer 72 (1993) 244-248
89. Faiss S., Pape U.F., Bohmig M., Dorffel Y., Mansmann U., Golder W., et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21 (2003) 2689-2696
90. Bernard B.F., Krenning E.P., Breeman W.A., Rolleman E.J., Bakker W.H., Visser T.J., et al. d-Lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. J Nucl Med 38 (1997) 1929-1933
91. 86Y-DOTA0)-d-Phe1-Tyr3-octreotide (SMT487) - a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 30 (2003) 510-518
92. De Jong M., Valkema R., Jamar F., Kvols L.K., Kwekkeboom D.J., Breeman W.A., et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 32 (2002) 133-140
93. Anthony L.B., Woltering E.A., Espenan G.D., Cronin M.D., Maloney T.J., and McCarthy K.E. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 32 (2002) 123-132
94. 111In-pentetreotide: initial observations and future directions. Cancer J Sci Am 4 (1998) 94-102
95. De Jong M., Breeman W.A., Bernard H.F., Kooij P.P., Slooter G.D., Van Eijck C.H., et al. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues. Q J Nucl Med 43 (1999) 356-366
96. 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors. J Nucl Med 44 (2003) 1-6
97. Valkema R., De Jong M., Bakker W.H., Breeman W.A., Kooij P.P., Lugtenburg P.J., et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med 32 (2002) 110-122
98. Kwekkeboom D.J., Mueller-Brand J., Paganelli G., Anthony L.B., Pauwels S., Kvols L.K., et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 46 Suppl 1 (2005) 62S-66S
99. Krenning E.P., Valkema R., Kooij P.P., Breeman W.A., Bakker W.H., deHerder W.W., et al. Scintigraphy and radionuclide therapy with [indium-111-labelled-diethyl triamine penta-acetic acid-d-Phe1]-octreotide. Ital J Gastroenterol Hepatol 31 Suppl 2 (1999) S219-S223
100. Lewington V.J. Targeted radionuclide therapy for neuroendocrine tumours. Endocr Relat Cancer 10 (2003) 497-501
101. Otte A., Herrmann R., Heppeler A., Behe M., Jermann E., Powell P., et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 26 (1999) 1439-1447
102. Virgolini I., Britton K., Buscombe J., Moncayo R., Paganelli G., and Riva P. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 32 (2002) 148-155
103. Modlin I.M., Kidd M., Latich I., Zikusoka M.N., and Shapiro M.D. Current status of gastrointestinal carcinoids. Gastroenterology 128 (2005) 1717-1751
104. 177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 23 (2005) 2754-2762
105. 90Y-labeled somatostatin analogs. J Nucl Med 46 Suppl 1 (2005) 13S-17S
106. Feldman J.M., Blinder R.A., Lucas K.J., and Coleman R.E. Iodine-131 metaiodobenzylguanidine scintigraphy of carcinoid tumors. J Nucl Med 27 (1986) 1691-1696
107. Prvulovich E.M., Stein R.C., Bomanji J.B., Ledermann J.A., Taylor I., and Ell P.J. Iodine-131-MIBG therapy of a patient with carcinoid liver metastases. J Nucl Med 39 (1998) 1743-1745
108. Mukherjee J.J., Kaltsas G.A., Islam N., Plowman P.N., Foley R., Hikmat J., et al. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG]. Clin Endocrinol (Oxf) 55 (2001) 47-60
109. Safford S.D., Coleman R.E., Gockerman J.P., Moore J., Feldman J., Onaitis M.W., et al. Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients. Cancer 101 (2004) 1987-1993
110. Hoefnagel C.A., Den Hartog Jager F.C., Van Gennip A.H., Marcuse H.R., and Taal B.G. Diagnosis and treatment of a carcinoid tumor using iodine-131 meta-iodobenzylguanidine. Clin Nucl Med 11 (1986) 150-152
111. Pathirana A.A., Vinjamuri S., Byrne C., Ghaneh P., Vora J., and Poston G.J. (131)I-MIBG radionuclide therapy is safe and cost-effective in the control of symptoms of the carcinoid syndrome. Eur J Surg Oncol 27 (2001) 404-408
112. Moertel C.G. Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol 1 (1983) 727-740
113. Kulke MH. Clinical presentation and management of carcinoid tumors. Hematol Oncol Clin North Am 2007;21:433-55; vii-viii.
114. Hobday T.R.J., Goldberg R., et al. Molecular markers in metastatic gastrointestinal neuroendocrine tumors. Proc Am Soc Clin Oncol 22 (2003) A1078
115. Kulke M.H., Bergsland E.K., Ryan D.P., Enzinger P.C., Lynch T.J., Zhu A.X., et al. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 24 (2006) 3555-3561
116. Eder Jr. J.P., Supko J.G., Clark J.W., Puchalski T.A., Garcia-Carbonero R., Ryan D.P., et al. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 20 (2002) 3772-3784
117. Bergers G., Javaherian K., Lo K.M., Folkman J., and Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284 (1999) 808-812
118. Kulke M.H., Stuart K., Enzinger P.C., Ryan D.P., Clark J.W., Muzikansky A., et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24 (2006) 401-406
119. Yao J.C., Phan A., Hoff P.M., Chen H.X., Charnsangavej C., Yeung S.C., et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 26 (2008) 1316-1323
120. Kulke M.L.H., Meropol N., et al. A phase 2 study to evaluate the efficacy and safety of SU11248 in patients with unresectable neuroendocrine tumors. Proc Am Soc Clin Oncol (2005) A4008